Patent US4919937A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4919937A Expired / Lapsed US ⏱️ 0.0 years remaining

Percutaneous administration of tamoxifen

Assignee: Individual
•
Filing: 1984-12-21
•
Granted: 1990-04-24
•
Expires: 2004-12-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Anti-estrogen drug of which the active product is comprised of 1 (p-dimethylaminoethoxyphenyl) trans-1-(p-hy-droxyphenyl)-2-phenylbut-1-ene, and present as a gel of the hydroalcoholic type which is percutaneously administrable. The above-mentioned active product may be associated to the progesterone. It is used for the treatment of breast affections, particularly benign cancerous affections of the breast.

Inventors

  • 👤 Pierre Mauvais-Jarvis
  • 👤 Frederique Kuttenn

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 14:50
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K31/00; A61K31/13; A61K31/135; A61K31/56; A61K31/57; A61K47/00; A61K47/30; A61K47/32; A61P; A61P17/00; A61P35/00

Claims Analysis

Total Claims: 3
Claim 1
Independent Claim 39 words
A method of treating conditions of the breast including the steps of: forming an aqueous alcoholic gel in which the active ingredient consists of 1-[4-(2-N-dimethylaminoethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenylbut-1-(Z)-ene; and administering percutaneously said aqueous alcoholic gel as an anti-estrogen drug to a breast.
Claim 2
Independent Claim 39 words
A method of treating conditions of the breast including the steps of: forming an aqueous alcoholic gel in which the active ingredient consists of 1-[4-(2-N-dimethylaminoethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenylbut-1-(Z)-ene; and administering percutaneously said aqueous alcoholic gel as an anti-estrogen drug to a breast.
Claim 3
Dependent Claim 19 words
The method of claim 1 wherein progesterone is added to said aqueous alcoholic gel to provide a synergistic effect.

References Cited (Backward Citations)

EP0002097A1 Cited
EP0054168A1 Cited
FR2515041A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-04-23 1993-10-23 1994-04-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-04-23 1997-10-23 1998-04-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-04-23 2001-10-23 2002-04-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag